Search Results

You are looking at 251 - 260 of 2,706 items for :

  • Refine by Access: All x
Clear All
Full access

Cancer-Related Fatigue: Definitions and Clinical Subtypes

Barbara F. Piper and David Cella

activities and poor quality of life. 42 One systematic review evaluated symptom prevalence in patients with incurable cancer. Increased levels of CRF were reported by patients with advanced malignancies 31 and in those with other illnesses or comorbidities

Full access

Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer

Sushmita Gordhandas, William A. Zammarrelli III, Eric V. Rios-Doria, Angela K. Green, and Vicky Makker

of all EC tumors. 11 Molecular subtyping has informed significant therapeutic advancements in advanced/recurrent EC, as outlined in this review, and has been increasingly exploited for risk stratification for optimal personalized treatment. The

Full access

Controversies in the Surgical Management of Renal Cancer

Michael P. Porter and Paul H. Lange

Statistics Review, 1975-2001. Bethesda, MD : National Cancer Institute ; 2004 . 2 Patard JJ Shvarts O Lam JS . Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience . J Urol 2004 ; 171

Full access

NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024

Featured Updates to the NCCN Guidelines

Jason Gotlib, Aaron T. Gerds, Peter Abdelmessieh, Haris Ali, Mariana Castells, Andrew Dunbar, Ruth Fein Revell, Tracy I. George, Steven Green, Krishna Gundabolu, Elizabeth Hexner, Tania Jain, Catriona Jamieson, Paul R. Kaesberg, Andrew T. Kuykendall, Yazan Madanat, Naveen Manchanda, Lucia Masarova, Jori May, Brandon McMahon, Sanjay R. Mohan, Kalyan V. Nadiminti, Stephen Oh, Jeanne Palmer, Ami Patel, Anand A. Patel, Nikolai Podoltsev, Lindsay Rein, Rachel Salit, Moshe Talpaz, Martha Wadleigh, Sarah Wall, Mary Anne Bergman, and Cindy Hochstetler

participation. To participate in this journal CE activity: (1) review the educational content; (2) take the posttest with a 66% minimum passing score and complete the evaluation at https://education.nccn.org/node/94849 ; and (3) view/print certificate

Full access

Accuracy of Referring Provider and Endoscopist Impressions of Colonoscopy Indication

Mariam Naveed, Meredith Clary, Chul Ahn, Nisa Kubiliun, Deepak Agrawal, Byron Cryer, Caitlin Murphy, and Amit G. Singal

cancer syndrome (based on chart review), given the high probability of misclassifying colonoscopy indication in these patients. The study was approved by the North Texas VA Institutional Review Board. Data Collection We considered 4 methods to

Full access

QIM19-146: A Multidisciplinary Approach to Conquer Central-Line Associated Blood Stream Infections: Establishing the Continuum of Prevention

Christine Wallace, Jennifer Sullivan, and Erin Supan

Chief Medical and Associate Chief Nursing Officers. A multidisciplinary group convened to standardize central line insertion and maintenance practices. Product review showed 20 different central line insertion kits and 6 different dressing kits

Full access

QIM19-123: Addressing Opportunities for Improving Care Cadence by Driving Interdepartmental Collaboration

Kimberly Byrwa-Neff, Wendi Waugh, and Rhondalyn Bomkamp

Background: Southern Ohio Medical Center (SOMC) is a community hospital in Portsmouth, Ohio. Review of data pertaining to breast care delivery demonstrated opportunities for improvement. Analysis of the cadence of care processes across departments

Full access

HSR19-082: Epidemiological Findings and Outcomes in Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations: A Meta-Analysis

Victoria Crossland, Aaron Galaznik, Huamao M. Lin, Dimitrios Tomaras, Shan Ashton Garib, Shuanglian Li, Hui Huang, and Anna Forsythe

approved for use on common mutations but none have been approved for EGFR exon 20 insertions, indicating a need for targeted therapy for this subpopulation. A systematic literature review (SLR) and meta-analysis were conducted to synthesize epidemiological

Full access

HSR19-106: Association Between Pathological Complete Responses and Long-Term Survival Outcomes Among Triple-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Cynthia Z. Qi, Min Huang, Amin Haiderali, Jipan Xie, Zheng-Yi Zhou, Eric Q. Wu, and Peter Fasching

long-term survival outcomes among patients with general BC and certain subtypes including triple negative BC (TNBC). To update and extend the evidence to assess the association of pCR and survival outcomes in TNBC, this study reviewed and summarized

Full access

QIM19-132: Trastuzumab Induced Cardiotoxicity: Are We Monitoring and Managing Appropriately?

Heather Katz, Hassaan Jafri, Emilia Cindy Leigh, Layana Biglow, Madhulika Urella, and Maria Tria Tirona

% from pretreatment values. Trastuzumab should be permanently discontinued for persistent (>8 weeks) LVEF decline or if trastuzumab is stopped > 3 times for cardiomyopathy (trastuzumab package insert). Methods: A retrospective chart review was